NPC1L1 (Niemann-Pick C1-like 1), the pharmacological target of the cholesterol-uptake inhibitor ezetimibe, is a transporter localized on the brush border of enterocytes. Although this protein plays a key role in intestinal uptake of sterols, multiple molecular events that underlie intestinal cholesterol absorption have not been fully characterized. Two proteins that might be involved in this process are NPC1 and NPC2 (Niemann-Pick disease type C proteins 1 and 2), which function in the endosomal/lysosomal cholesterol egress pathway and whose deficiency results in NPC (Niemann-Pick type C) disease. The involvement of these proteins in intestinal cholesterol absorption was examined in mutant mice lacking either NPC1 or NPC2. Our data indicate that deficiencies in either protein do not have an effect on cholesterol uptake or absorption. This contrasts with recent results obtained for the fruitfly Drosophila melanogaster, which indicate that a deficiency of NPC1 (dNPC1a being its Drosophila homologue) leads to activation of an NPC1L1 (Drosophila homologue dNPC1b)-independent cholesterol uptake pathway, underscoring fundamental differences in mammalian and non-mammalian cholesterol metabolism.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2049080 | PMC |
| http://dx.doi.org/10.1042/BJ20071167 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lysosomal damage due to cholesterol accumulation triggers immunogenic cell death.
Autophagy
December 2024
Centre de Recherche des Cordeliers, INSERM UMRS 1138, Sorbonne Université, Université Paris Cité, Équipe labellisée par la Ligue contre le Cancer, Institut Universitaire de France, Paris, France.
Cholesterol serves as a vital lipid that regulates numerous physiological processes. Nonetheless, its role in regulating cell death processes remains incompletely understood. In this study, we investigated the role of cholesterol trafficking in immunogenic cell death.
View Article and Find Full Text PDFInvestigating p.Ala1035Val in NPC1: New Cellular Models for Niemann-Pick Type C Disease.
Int J Mol Sci
November 2024
Research and Development Unit, Department of Human Genetics, National Institute of Health Doutor Ricardo Jorge (INSA, I. P.), Rua Alexandre Herculano 321, 4000-055 Porto, Portugal.
Article Synopsis
- * The p.Ala1035Val variant is the most common in Portugal and is linked to a potential SNP (p.Ile858Val) that may affect disease progression.
- * Research using in vitro models reveals that the p.Ala1035Val variant, especially when combined with p.Ile858Val, shows decreased lysosomal trafficking similar to p.Ile1061Thr, suggesting the need for new therapeutic approaches.
Infantile Cholestatic Jaundice: A Variant of Niemann-Pick Disease Type C2.
Cureus
September 2024
Paediatrics, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND.
Niemann-Pick disease is an autosomal recessive lysosomal lipid storage disorder disease caused by mutations in either Niemann-Pick disease type C1 (NPC1) or the NPC2 gene. It has a wide range of symptoms that vary in severity, classified into three main types: A, B, and C1 and C2, based on genetics and the symptoms and signs. The usual presentation in the neonatal period is cholestatic jaundice, subsequently, it will develop hepatosplenomegaly in infancy, failure to thrive, ataxia, hypotonia, seizure, difficulty in speech, swallowing, and recurrent respiratory tract infection.
View Article and Find Full Text PDFMolecular determinants of phospholipid treatment to reduce intracellular cholesterol accumulation in NPC1 deficiency.
J Biol Chem
November 2024
Department of Nutritional Sciences, Rutgers University, New Brunswick, New Jersey, USA; Rutgers Center for Lipid Research, Rutgers University, New Brunswick, New Jersey, USA. Electronic address:
Article Synopsis
- - Niemann-Pick type C (NPC) disease results from mutations in NPC1 or NPC2 genes, leading to the accumulation of cholesterol in late endosomes/lysosomes, and researchers are exploring LBPA (lysobisphosphatidic acid) as a therapeutic agent to reduce this accumulation.
- - Studies indicate that different stereoisomers of LBPA are effective in reducing cholesterol levels in NPC1-deficient human fibroblast cells, with the presence of an 18:1 acyl chain being particularly significant for enhancing cholesterol clearance.
- - Further experiments suggest that while phosphatidylglycerol (PG) can also reduce cholesterol, it does not convert to LBPA effectively, highlighting that LBPA itself is essential for promoting cholesterol
Advances in research on potential therapeutic approaches for Niemann-Pick C1 disease.
Front Pharmacol
August 2024
Department of Gastroenterology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Article Synopsis
- - Niemann-Pick disease type C1 (NP-C1) is a rare genetic disorder caused by mutations in the NPC1 or NPC2 genes, leading to issues with cholesterol transport and resulting in symptoms like enlarged liver and spleen, neurodegeneration, and loss of motor control.
- - Although NP-C1 is rare, researchers have been actively working on various potential therapies over the past 20 years, which include small molecule treatments, cell-based methods, and gene therapy.
- - The development of these treatments is still in the early experimental stages, presenting complex challenges that researchers aim to address in order to slow the disease's progression.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!